カテゴリ： GlobalData, アメリカ, 企業調査

PositiveID Corp (PSID)-医療機器分野：企業M&A・提携分析

◆英語タイトル：PositiveID Corp (PSID) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011304
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月22日
◆ページ数：74
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
PositiveID Corp (PositiveID) is a medical device company that develops biological detection and molecular diagnostic systems. The company develops microfluidic systems for automated preparation and performance of biological assays. Its products include firefly Dx and m-band. PositiveID’s technologies offer research and white papers, which include identification of zika virus on firefly Dx, PSID market opportunities, and ricin detection assay. PositiveID’s technology is used for airborne pathogen detection, rapid biological diagnostics and sample preparation applications. The company operates in Delray Beach, Florida, Pleasanton, and California, the US . PositiveID is headquartered in Delray Beach, Florida, the US.

PositiveID Corp (PSID) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PositiveID Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
PositiveID Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 7
PositiveID Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
PositiveID Corp, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
PositiveID Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
PositiveID Corp, Medical Equipment, Deal Details 11
Partnerships 11
PositiveID Enters Into Licensing Agreement With Smart Glucose Meter For iglucose Technology 11
PositiveID Enters Into Licensing Agreement With Siemens 12
PositiveID Enters into Co-Development Agreement with USSOCOM 13
PositiveID Enters Into Agreement With HMD BioMedical 14
PositiveID Enters Into An Agreement With Connected Development 15
Equity Offering 16
PositiveID Announces Private Placement Of Shares For US$5 Million 16
PositiveID Completes Second Tranche Private Placement Of Series F Convertible Preferred Stock 17
PositiveID Completes Private Placement Of Common Stock For US$2.5 Million 19
PositiveID Completes Final Tranche Of Private Placement Of Series B Preferred Stock For US$0.2 Million 21
PositiveID Completes Private Placement Of Shares For US$4.2 Million 22
Debt Offering 23
PositiveID Completes First Tranche Of Private Placement Of Convertible Debentures For US$0.6 Million 23
Asset Transactions 24
ExcitePCR to Acquire FireflyDX Technology from PositiveID 24
PositiveID Completes Sale Of VeriChip And Health Link Businesses To VeriTeQ 25
Acquisition 27
PositiveID Acquires Thermomedics from Sanomedics 27
PositiveID Corporation Sells Stake In VeriTeQ For US$0.75 Million 28
PositiveID Completes Acquisition Of MicroFluidic Systems 29
PositiveID Corp – Key Competitors 30
PositiveID Corp – Key Employees 31
PositiveID Corp – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 34
Financial Announcements 34
Nov 14, 2017: PositiveID Reports Third Quarter 2017 Results; Revenues increase 38% Year over Year 34
Aug 15, 2017: PositiveID Reports Second Quarter 2017 Results 36
May 16, 2017: PositiveID Reports First Quarter 2017 Results 37
May 01, 2017: PositiveID Announces Highlights for First Quarter 2017 38
Apr 03, 2017: PositiveID Reports 2016 Results; Revenue of $5.6 Million, up 89% Year over Year 39
Nov 21, 2016: PositiveID Reports Revenue of $4.6 Million for First Nine Months of 2016, Up 70% from $2.7 Million for First Nine Months of 2015 40
Sep 27, 2016: PositiveID Announces Highlights for Third Quarter 2016 41
Aug 15, 2016: PositiveID Reports Q2 2016 Revenue of $1.8 Million, Up from $51 Thousand in Q2 2015 42
Jul 12, 2016: PositiveID Announces Highlights for First Half of 2016 43
May 17, 2016: PositiveID Reports Q1 2016 Revenue of $1.7 Million, Up from $0.1M in Q1 2015 44
Apr 12, 2016: PositiveID Reports 2015 Revenue of $2.9 Million, Up 211% Year over Year 45
Corporate Communications 47
Sep 26, 2017: PositiveID Subsidiary ExcitePCR Announces Board of Advisors 47
Aug 24, 2017: PositiveID’s Subsidiary, ExcitePCR, Hires Thirty-Year Marketing Veteran, David L. Politis, as its Chief Marketing & Sales Officer 48
May 30, 2017: PositiveID Subsidiary ExcitePCR Names Chief Science Officer 49
Aug 02, 2016: PositiveID Adds GenArraytion CEO R. Paul Schaudies, Ph.D. to its Board of Advisors 50
May 31, 2016: PositiveID Adds Benedikt von Braunmuhl to its Board of Advisors 51
Legal and Regulatory 52
May 04, 2016: PositiveID Launches New Website for E-N-G Mobile Systems 52
Product News 53
Nov 27, 2017: PositiveID to Present at the LD MICRO “Main Event” Investor Conference 53
Sep 18, 2017: PositiveID’s ExcitePCR Subsidiary CEO to Speak on National Academies of Science, Engineering, and Medicine Panel Today 54
Apr 24, 2017: PositiveID Updates Report for its Molecular Diagnostics, Mobile Labs and Medical Device Businesses with Addressable Markets Exceeding $30 Billion 55
Jan 25, 2017: PositiveID to Present at RedChip’s Global Online Growth Conference 56
Nov 29, 2016: PositiveID Updates Market Opportunities Report for its Molecular Diagnostics, Medical Device and Mobile Labs Businesses 57
Oct 19, 2016: PositiveID to Present at RedChip’s Global Online Growth Conference on October 20th 58
Sep 15, 2016: PositiveID to Present at the 2016 Aegis Growth Conference on September 22nd 59
Aug 08, 2016: PositiveID to Exhibit at the Military Health System Research Symposium August 15-18 60
Jul 14, 2016: PositiveID to Present at RedChip’s Small Stocks, Big Money Investor Conference 61
May 26, 2016: PositiveID to Present at the 2016 Marcum MicroCap Conference on June 1st 62
03/15/2016: PositiveID Achieves Major Firefly Dx Development Milestone 63
Other Significant Developments 64
Nov 28, 2017: PositiveID Projects Revenue Growth of More Than 30% Year-over-Year through First Quarter of 2018 64
Oct 09, 2017: PositiveID Announces Highlights for the Third Quarter of 2017 65
Jun 28, 2017: PositiveID Announces Highlights for the First Half of 2017 66
Mar 14, 2017: PositiveID’s E-N-G Mobile Systems’ 2017 Bookings Through February Total $1.7 Million, Up More than 200% from Prior Quarter 67
Feb 21, 2017: PositiveID Announces 2016 Highlights 68
Dec 27, 2016: PositiveID’s E-N-G Mobile Systems to Start 2017 with $3.9M of Orders in Backlog and Pipeline 69
Oct 18, 2016: PositiveID’s E-N-G Mobile Systems’ Orders for Vehicle Production and Modification in Q3 Grew 240% over the First Half of 2016 70
Jun 21, 2016: PositiveID’s Mobile Lab Business Completed 80 Projects in the First Half of 2016 71
Jan 11, 2016: PositiveID Announces 2015 Highlights and 2016 Outlook 72
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
PositiveID Corp, Medical Equipment, Key Facts, 2016 2
PositiveID Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
PositiveID Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
PositiveID Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 7
PositiveID Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
PositiveID Corp, Deals By Market, 2011 to YTD 2017 9
PositiveID Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
PositiveID Enters Into Licensing Agreement With Smart Glucose Meter For iglucose Technology 11
PositiveID Enters Into Licensing Agreement With Siemens 12
PositiveID Enters into Co-Development Agreement with USSOCOM 13
PositiveID Enters Into Agreement With HMD BioMedical 14
PositiveID Enters Into An Agreement With Connected Development 15
PositiveID Announces Private Placement Of Shares For US$5 Million 16
PositiveID Completes Second Tranche Private Placement Of Series F Convertible Preferred Stock 17
PositiveID Completes Private Placement Of Common Stock For US$2.5 Million 19
PositiveID Completes Final Tranche Of Private Placement Of Series B Preferred Stock For US$0.2 Million 21
PositiveID Completes Private Placement Of Shares For US$4.2 Million 22
PositiveID Completes First Tranche Of Private Placement Of Convertible Debentures For US$0.6 Million 23
ExcitePCR to Acquire FireflyDX Technology from PositiveID 24
PositiveID Completes Sale Of VeriChip And Health Link Businesses To VeriTeQ 25
PositiveID Acquires Thermomedics from Sanomedics 27
PositiveID Corporation Sells Stake In VeriTeQ For US$0.75 Million 28
PositiveID Completes Acquisition Of MicroFluidic Systems 29
PositiveID Corp, Key Competitors 30
PositiveID Corp, Key Employees 31
PositiveID Corp, Other Locations 32
PositiveID Corp, Subsidiaries 32

★海外企業調査レポート[PositiveID Corp (PSID)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Burger-In Oy：企業の戦略・SWOT・財務情報
    Burger-In Oy - Strategy, SWOT and Corporate Finance Report Summary Burger-In Oy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Hydrogenics Corp (HYG)：企業の財務・戦略的SWOT分析
    Hydrogenics Corp (HYG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Avanos Medical Inc (HYH)：医療機器：M&Aディール及び事業提携情報
    Summary Avanos Medical Inc (Avanos Medical), formerly Halyard Health Inc is a medical technology company that provides medical devices and equipments. The company offers clinically-superior products and solutions in digestive health, pain management, infection prevention, surgical solutions and IV t …
  • QinetiQ Group Plc：企業の戦略・SWOT・財務情報
    QinetiQ Group Plc - Strategy, SWOT and Corporate Finance Report Summary QinetiQ Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Leukemia & Lymphoma Society Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary The Leukemia & Lymphoma Society Inc (LLS) is a voluntary health organization that focuses on funding research for identifying cure for blood cancer. The organization also assures access to treatments for blood cancer patients. Its offers patient support, health education, policy advocacy, an …
  • Gamma Medica Inc：医療機器：M&Aディール及び事業提携情報
    Summary Gamma Medica Inc (Gamma Medica), formerly Gamma Medica Ideas Inc is a medical device company that offers imaging solutions. The company designs, develops and manufactures imaging systems for clinical and pre-clinical applications. It offers lumagem, lumagem mbi workflow, lumagem procedure ov …
  • Blackthorn Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Blackthorn Therapeutics Inc (Blackthorn Therapeutics) is a clinical stage biopharmaceutical company that discovers and develops targeted treatments for neurobehavioral disorders. The company offers products such as BTRX-246040, an NOPR antagonist; and BTRX-335140, a KOR antagonist. It uses I …
  • NaviNet Inc：企業の戦略的SWOT分析
    NaviNet Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Stellar Resources Ltd
    Stellar Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Stellar Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Cipher Pharmaceuticals Inc (CPH)：企業の財務・戦略的SWOT分析
    Summary Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company provides products such as actikerall, a topical solution indicated for the treatment of hyperkeratotic actinic keratosis; beteflam, a topical patch used for the treatment of mild to …
  • Canary Wharf Group Plc：企業の戦略・SWOT・財務情報
    Canary Wharf Group Plc - Strategy, SWOT and Corporate Finance Report Summary Canary Wharf Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Plenus Company Limited
    Plenus Company Limited - Strategy, SWOT and Corporate Finance Report Summary Plenus Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • SANUWAVE Health Inc (SNWV)：企業の財務・戦略的SWOT分析
    Summary Sanuwave Health Inc (Sanuwave), formerly Rub Music Enterprises Inc, is a medical device company that develops and commercializes noninvasive biological response activating devices. The company offers products such as dermapace, which is used in the treatment of chronic and acute conditions o …
  • Sanmina Corporation (SANM)：企業の財務・戦略的SWOT分析
    Sanmina Corporation (SANM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Aeroflot OAO：企業の戦略・SWOT・財務情報
    Aeroflot OAO - Strategy, SWOT and Corporate Finance Report Summary Aeroflot OAO - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • TeneoBio Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary TeneoBio Inc (TeneoBio), formerly OMT Therapeutics Inc is a biotechnology company. The company develops biologics, human heavy chain antibodies as therapeutics that targets the cancer, autoimmunity, and infectious diseases. Its pre-clinical pipeline portfolio includes antibodies such as mult …
  • Randox Laboratories Ltd：企業の製品パイプライン分析2018
    Summary Randox Laboratories Ltd (Randox) is a clinical diagnostic company that manufactures and provides clinical diagnostic solutions to laboratories. The company’s products include biochip analyzers, biochip immunoassays, clinical chemistry analyzers and diagnostic reagents among others. It offers …
  • JSFC Sistema (AFKS)：石油・ガス：M&Aディール及び事業提携情報
    Summary JSFC Sistema (Sistema) is a diversified holding company which offers a wide range of consumer services in Russia and the Commonwealth of Independent States (CIS).The company undertakes businesses in various sectors, including telecommunications, high technology, real estate development, reta …
  • Alps Industries Ltd.：企業の戦略・SWOT・財務情報
    Alps Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary Alps Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Tesla Motors, Inc.：企業の戦略・SWOT・財務情報
    Tesla Motors, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tesla Motors, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆